Creating models for primary tauopathies sounds simple enough. Select a human tau gene variant that causes disease, stick it where the endogenous mouse gene sits in its genome, then wait a few months ...

Now that doctors are prescribing anti-amyloid therapies for Alzheimer’s disease, scientists have begun to focus their energy on the other pathological hallmark of AD, neurofibrillary tangles. While ...

From April 24-25, the Tau Global Conference, a.k.a. Tau2025, drew 600 people to a hotel in Hyde Park, London, with 500 more following the science online. Attendance well surpassed Tau2020, the first, ...

Neurofibrillary tangles mark Alzheimer’s disease and a plethora of primary tauopathies. How best to study them in the lab? Most mouse tauopathy models overexpress the human tau protein and are highly ...

In a milestone for Alzheimer’s disease diagnosis and care, the U.S. Food and Drug Administration on May 16 cleared for marketing the first AD blood test. Fujirebio’s Lumipulse G p-tau217/Aβ42 ...

As awareness about dementia continues to grow worldwide, a spate of online courses aims to help both health professionals and the general public understand Alzheimer’s and related diseases. Below is a ...

As biomarker testing becomes more common in Alzheimer’s research, scientists face the tricky question of whether to disclose results. In studies of hypothetical scenarios, including a recent survey ...

What are physicians learning from their early experiences prescribing amyloid immunotherapy? In the May 12 JAMA Neurology, Joy Snider and Suzanne Schindler and colleagues at Washington University, St.